CN112076535A - Biological enzyme-linked filter medium and preparation method thereof - Google Patents
Biological enzyme-linked filter medium and preparation method thereof Download PDFInfo
- Publication number
- CN112076535A CN112076535A CN202010943318.9A CN202010943318A CN112076535A CN 112076535 A CN112076535 A CN 112076535A CN 202010943318 A CN202010943318 A CN 202010943318A CN 112076535 A CN112076535 A CN 112076535A
- Authority
- CN
- China
- Prior art keywords
- glass fiber
- fiber membrane
- filter
- filter plate
- filter medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
- B01D2239/04—Additives and treatments of the filtering material
- B01D2239/0414—Surface modifiers, e.g. comprising ion exchange groups
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Filtering Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a biological enzyme-linked filter medium and a preparation method thereof, the filter medium is formed by laminating surface-modified glass fiber membranes, the number of laminated layers is 1-30, and the diameter is 5-20cm, and the preparation method comprises the following steps: step 1, placing a glass fiber membrane to be modified with a certain thickness in a muffle furnace, roasting at the temperature of 300-500 ℃ for 2h, taking out and cooling to room temperature to obtain a glass fiber membrane B; step 2, spreading the glass fiber membrane B in a glass reaction vessel, slowly pouring the treatment liquid into the glass reaction vessel, and enabling the glass fiber membrane B to be saturated by soaking the treatment liquid in the glass reaction vessel and submerging the treatment liquid in the glass fiber membrane B to obtain a glass fiber membrane C; and 3, drying the glass fiber membrane C to obtain the glass fiber membrane with the modified surface, so that the plasma filtering medium has the advantages that the plasma can be filtered by the filter medium, the filtered plasma can be re-infused into the body of a patient, the problem of insufficient plasma inventory is solved, and the problem of plasma infection of other people is reduced.
Description
Technical Field
The invention belongs to the technical field of filter media, and particularly relates to a biological enzyme-linked filter medium and a preparation method thereof.
Background
Currently, plasmapheresis is the separation of patient plasma by a plasma separator or centrifuge, followed by discarding and subsequent replenishment of plasma substitutes. However, when the plasma of other people is supplemented, the situation of insufficient plasma stock is easily met, or the problem of infection caused by inputting the plasma of other people is easily solved, so that the treatment is delayed and the infection is easy to occur.
Disclosure of Invention
The invention provides a biological enzyme-linked filter medium and a preparation method thereof, which can filter plasma by means of the filter medium, and the filtered plasma can be re-infused into a patient body, thereby solving the problem of insufficient plasma inventory and simultaneously reducing the problem of plasma infection caused by other people.
The technical scheme of the invention is realized as follows: a biological enzyme-linked filter medium is composed of surface modified glass fibre membranes laminated by 1-30 layers and 5-20cm in diameter.
A preparation method of a biological enzyme-linked filter medium comprises the following steps:
and 3, drying the glass fiber membrane C to obtain the surface-modified glass fiber membrane.
As a preferred embodiment, the treatment solution is prepared by dissolving uricase lyophilized powder in purified water, and shaking in a constant temperature shaker at a temperature of less than 10 deg.C for 20min to obtain the treatment solution.
As a preferred embodiment, the weight of the uricase freeze-dried powder is 5-10mg, and the volume of the purified water is 30 ml.
As a preferred embodiment, the uricase freeze-dried powder comprises 88 percent of uricase and 12 percent of buffer salt solution, wherein the activity of the uricase is more than or equal to 10U/mg.
As a preferred embodiment, the preparation method of the treatment fluid comprises the steps of dissolving oxalate decarboxylase freeze-dried powder in purified water, and oscillating 30min in a constant temperature oscillator under the condition of temperature less than 10 ℃ to obtain the treatment fluid.
As a preferred embodiment, the weight of the oxalate decarboxylase freeze-dried powder is 5-10mg, and the volume of the purified water is 30 ml.
In a preferred embodiment, in step 2, before the treatment solution is poured into the glass reaction vessel, the reaction solution is firstly poured into the glass reaction vessel, and after shaking for 2 hours in a constant temperature shaker at 30 ℃, the reaction solution is taken out, dried at 60 ℃, taken out, laid in the glass reaction vessel, and then the treatment solution is poured.
As a preferred embodiment, the reaction solution is a glutaraldehyde solution having a concentration of 1.0% and a volume of 100 ml.
The utility model provides a be provided with this biological enzyme allies oneself with filter media's filter, which comprises an upper cover, lower cover and filter core, the bottom of lower cover is provided with the hemorrhage mouth, be provided with the base in the lower cover, the joint is provided with the filter plate fixing base in the base, the filter plate fixing base is the ascending cartridge type setting of opening, the bottom surface of filter plate fixing base is provided with a plurality of through-holes, the filter core is placed in the filter plate fixing base, the filter core includes first filter plate and second filter plate, first filter plate is this biological enzyme allies oneself with filter media, the second filter plate is microfiltration membrane, the second filter plate sets up in the below of first filter plate, the upper cover lid closes and sets up in the top of lower cover, the top.
After the technical scheme is adopted, the invention has the beneficial effects that:
according to the invention, the plasma can be filtered through the filter, and the filtered plasma can be re-infused into the body of a patient, so that the problem of insufficient plasma inventory is solved, and the problem of plasma infection caused by other people is also reduced.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a schematic structural diagram of the present invention.
In the figure, 1-upper cover; 2-lower cover; 12-bleeding outlet; 13-blood inlet; 9-an exhaust port; 6-a first filter plate; 7-a second filter plate; 8-filter plate fixing seat; 15-a through hole; 14-base.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
According to the figure 1, the biological enzyme-linked filter medium is formed by laminating surface-modified glass fiber membranes, the number of the laminated layers is 1-30, and the diameter of the glass fiber membranes is 5-20 cm.
The preparation method of the biological enzyme-linked filter medium comprises the following steps:
step 3, paving the glass fiber membrane B in a glass reaction vessel, slowly pouring the treatment liquid obtained in the step 2 into the glass reaction vessel, and enabling the treatment liquid to submerge the glass fiber membrane B to saturate the glass fiber membrane B to obtain a glass fiber membrane C;
and 3, putting the glass fiber membrane C into a full-automatic freeze dryer for freeze drying, taking out after freeze drying is completed to obtain the glass fiber membrane with the modified surface, and refrigerating the modified glass fiber membrane at a low temperature for later use.
Gout is a purine metabolic disease characterized by deposition of sodium urate crystals in joints and surrounding tissues caused by persistent hyperuricemia, and can involve joint deformity caused by the joints and chronic interstitial nephritis, renal calculus and even uremia caused by kidney involvement. Hyperuricemia is considered to be the pre-state and biochemical basis for the development of gout, and therefore, uric acid lowering therapy is the main means for preventing and controlling gout attack. The uric acid oxidase medicines are novel medicines for reducing uric acid in recent years, can quickly degrade uric acid in human serum and accelerate dissolution of tophus, thereby effectively controlling the attack of gout, and can be used for treating other intractable gout patients who are ineffective or contraindicated in reducing uric acid.
The uricase freeze-dried powder in the embodiment comprises 88% of uricase and 12% of buffer salt solution, wherein the activity of the uricase is more than or equal to 10U/mg. Urate oxidase is used as ligand, is combined on a carrier, and forms a biological enzyme-linked filter medium for treating gout diseases. The biological enzyme-linked filtration medium can quickly oxidize uric acid into allantoic acid, and the allantoic acid is not absorbed by renal tubules and excreted. Has good effect on hyperuricemia caused by nodular gout, urinary calculus and kidney disease failure.
The utility model provides a be provided with this biological enzyme allies oneself with filter media's filter, including upper cover 1, lower cover 2 and filter core, the bottom of lower cover 2 is provided with bleeding mouth 12, be provided with base 14 in the lower cover 2, the joint is provided with filter plate fixing base 8 in the base 14, filter plate fixing base 8 is the ascending cartridge type setting of opening, the bottom surface of filter plate fixing base 8 is provided with a plurality of through-holes 15, the filter core is placed in filter plate fixing base 8, the filter core includes first filter plate 6 and second filter plate 7, first filter plate 6 is this biological enzyme allies oneself with filter media, second filter plate 7 is microfiltration membrane, second filter plate 7 sets up in the below of first filter plate 6, upper cover 1 lid closes and sets up in the top of lower cover 2, the top of upper cover 1 is provided with into blood mouth 13 and gas.
Firstly, a microfiltration membrane is placed in a filter plate fixing seat 8, then a modified glass fiber membrane is laminated to 30 layers and then placed above the microfiltration membrane, the filter plate fixing seat 8 is clamped in a base 14, an upper cover 1 is covered, the plasma of a patient is input from a blood inlet 12, after the plasma of the patient is filtered by a filter, uric acid is rapidly oxidized to become allantoic acid which is not absorbed by renal tubules and is excreted out of the body, the filtered plasma is output from a blood outlet 13 and is re-input into the body of the patient, and the mode not only can solve the condition of insufficient plasma in a plasma reservoir, but also can reduce the possibility of infection of the patient due to the input of other plasma.
According to the invention, the plasma uric acid value after passing through the filter is detected, and the detection results are shown in the following table:
according to the table, the plasma uric acid level after being filtered by the filter is obviously reduced, so that the surface modified glass fiber is used in the filter, and the surface modified glass fiber has obvious filtering capacity for the uric acid level in the plasma of a patient.
Example 2
A biological enzyme-linked filter medium is composed of surface modified glass fibre membranes laminated by 1-30 layers and 5-20cm in diameter.
The preparation method of the biological enzyme-linked filter medium comprises the following steps:
and 2, pouring a glutaraldehyde solution into the glass reaction vessel with the glass fiber membrane B, wherein the concentration of the glutaraldehyde solution is 1.0%, the volume of the glutaraldehyde solution is 100ml, oscillating the glutaraldehyde solution in a constant-temperature oscillator for 2 hours at the temperature of 30 ℃, taking out the glutaraldehyde solution, drying the glutaraldehyde solution at the temperature of 60 ℃, taking out the glutaraldehyde solution, and spreading the glutaraldehyde solution in the glass reaction vessel again.
And 3, dissolving 5mg of oxalate decarboxylase freeze-dried powder in 30ml of purified water, and oscillating for 30min in a constant-temperature oscillator at the temperature of less than 10 ℃ to obtain a treatment solution.
Step 4, slowly pouring the treatment liquid into the glass reaction vessel dried at 60 ℃ in the step 2, and oscillating for 2min in a constant temperature oscillator to obtain a glass fiber membrane C;
and 3, drying the glass fiber membrane C at normal temperature to obtain the surface-modified glass fiber membrane, and drying at normal temperature for later use.
The utility model provides a be provided with this biological enzyme allies oneself with filter media's filter, including upper cover 1, lower cover 2 and filter core, the bottom of lower cover 2 is provided with bleeding mouth 12, be provided with base 14 in the lower cover 2, the joint is provided with filter plate fixing base 8 in the base 14, filter plate fixing base 8 is the ascending cartridge type setting of opening, the bottom surface of filter plate fixing base 8 is provided with a plurality of through-holes 15, the filter core is placed in filter plate fixing base 8, the filter core includes first filter plate 6 and second filter plate 7, first filter plate 6 is this biological enzyme allies oneself with filter media, second filter plate 7 is microfiltration membrane, second filter plate 7 sets up in the below of first filter plate 6, upper cover 1 lid closes and sets up in the top of lower cover 2, the top of upper cover 1 is provided with into blood mouth 13 and gas.
Firstly put microporous filter membrane into filter plate fixing base 8, after laminating the glass fiber membrane after will modifying to 30 layers, put into microporous filter membrane's top, with filter plate fixing base 8 block in base 14, lid upper cover 1 closes, import patient's plasma by going into blood mouth 12, patient's plasma is through the filtration of filter after, the content of the chinese herbal acid value in plasma has been reduced, can be used to the filtration of kidney stone patient plasma, filtered plasma is exported by going out blood mouth 13, in infusing patient's health again, the not enough condition of plasma in the plasma storehouse has both been solved to this mode, can reduce the possibility that the patient takes place the infection because of importing other people's plasma again.
According to the invention, the detection result of the oxalic acid value of the blood plasma after passing through the filter is shown in the following table:
according to the table, the oxalic acid value content of the blood plasma after being filtered by the filter is obviously reduced, so that the surface modified glass fiber is used in the filter, and the oxalic acid value in the blood plasma of a patient is obviously filtered.
In the description of the present invention, it is to be understood that the terms "longitudinal", "lateral", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like, indicate orientations or positional relationships based on those shown in the drawings, and are used merely for convenience of description and for simplicity of description, and do not indicate or imply that the referenced devices or elements must have a particular orientation, be constructed in a particular orientation, and be operated, and thus, are not to be construed as limiting the present invention. In the description of the present invention, unless otherwise specified and limited, it is to be noted that the terms "mounted," "connected," and "connected" are to be interpreted broadly, and may be, for example, a mechanical connection or an electrical connection, a communication between two elements, a direct connection, or an indirect connection via an intermediate medium, and specific meanings of the terms may be understood by those skilled in the art according to specific situations.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The biological enzyme-linked filter medium is characterized by being formed by laminating surface-modified glass fiber membranes, wherein the number of the laminated layers is 1-30, and the diameter of each glass fiber membrane is 5-20 cm.
2. A preparation method of a biological enzyme-linked filter medium is characterized by comprising the following steps:
step 1, placing a glass fiber membrane to be modified with the thickness of 0.2-0.5mm in a muffle furnace, roasting for 2 hours at the temperature of 300-500 ℃, taking out and cooling to room temperature to obtain a glass fiber membrane B;
step 2, spreading the glass fiber membrane B in a glass reaction vessel, slowly pouring the treatment liquid into the glass reaction vessel, and enabling the glass fiber membrane B to be saturated by soaking the treatment liquid in the glass reaction vessel and submerging the treatment liquid in the glass fiber membrane B to obtain a glass fiber membrane C;
and 3, drying the glass fiber membrane C to obtain the surface-modified glass fiber membrane.
3. The method for preparing a bio-enzyme-linked filter medium according to claim 2, wherein the treatment solution is prepared by dissolving uricase lyophilized powder in purified water, and shaking in a constant temperature shaker at a temperature of less than 10 ℃ for 20 min.
4. The method for preparing a bio-enzyme-linked filter medium according to claim 3, wherein the weight of the taken uricase lyophilized powder is 5-10mg, and the volume of the taken purified water is 30 ml.
5. The method for preparing a bio-enzyme-linked filter medium according to claim 3, wherein the uricase lyophilized powder comprises 88% of uricase and 12% of buffer salt solution, wherein the activity of the uricase is more than or equal to 10U/mg.
6. The method for preparing a bio-enzyme-linked filter medium according to claim 2, wherein the treatment solution is prepared by dissolving oxalate decarboxylase lyophilized powder in purified water, and oscillating the solution in a constant temperature oscillator at a temperature of less than 10 ℃ for 30 min.
7. The method for preparing a bio-enzyme-linked filter medium as claimed in claim 6, wherein the weight of the oxalate decarboxylase lyophilized powder is 5-10mg, and the volume of the purified water is 30 ml.
8. The method according to claim 6, wherein in step 2, before the treatment solution is poured into the glass reaction vessel, the reaction solution is poured into the glass reaction vessel, and after shaking for 2 hours in a constant temperature shaker at 30 ℃, the reaction solution is taken out, dried at 60 ℃, taken out, and spread in the glass reaction vessel, and then the treatment solution is poured.
9. The method for preparing a biological enzyme-linked filter medium as claimed in claim 8, wherein the reaction solution is glutaraldehyde solution, and the concentration of the glutaraldehyde solution is 1.0% by volume, which is 100 ml.
10. The utility model provides a be provided with this biological enzyme allies oneself with filter media's filter, a serial communication port, including upper cover, lower cover and filter core, the bottom of lower cover is provided with the hemorrhage mouth, is provided with the base in the lower cover, the joint is provided with the filter plate fixing base in the base, the filter plate fixing base is the ascending cartridge type setting of opening, the bottom surface of filter plate fixing base is provided with a plurality of through-holes, the filter core is placed in the filter plate fixing base, the filter core includes first filter plate and second filter plate, first filter plate is this biological enzyme allies oneself with filter media, the second filter plate is microfiltration membrane, the second filter plate sets up in the below of first filter plate, the upper cover lid closes and sets up in the top of lower cover, the top of upper cover is provided with into blood mouth and gas vent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010943318.9A CN112076535B (en) | 2020-09-09 | 2020-09-09 | Biological enzyme-linked filter medium and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010943318.9A CN112076535B (en) | 2020-09-09 | 2020-09-09 | Biological enzyme-linked filter medium and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112076535A true CN112076535A (en) | 2020-12-15 |
| CN112076535B CN112076535B (en) | 2022-01-07 |
Family
ID=73731670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010943318.9A Active CN112076535B (en) | 2020-09-09 | 2020-09-09 | Biological enzyme-linked filter medium and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076535B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112076359A (en) * | 2020-09-14 | 2020-12-15 | 江苏恰瑞生物科技有限公司 | Plasma adsorption filtering device for treating kidney stone and filtering method thereof |
| CN116421808A (en) * | 2023-03-09 | 2023-07-14 | 江苏恰瑞生物科技有限公司 | Plasma adsorption and filtration device for asthma treatment and filtration method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2199351C1 (en) * | 2001-09-04 | 2003-02-27 | Петрик Виктор Иванович | Method of plasma blood clearance from uric acid and creatinine |
| CN1674955A (en) * | 2002-08-13 | 2005-09-28 | 阿尔比奥技术公司 | Selective plasma exchange therapy |
| CN104168934A (en) * | 2012-01-19 | 2014-11-26 | 贝克斯特国际公司 | Method and composition for removing uremic toxins in dialysis processes |
| CN106540344A (en) * | 2016-12-23 | 2017-03-29 | 上海江夏血液技术有限公司 | For treating the plasma filtering device and method of acute cerebral infarction |
| CN109091955A (en) * | 2018-08-07 | 2018-12-28 | 苏州华龙化工有限公司 | A kind of preparation method of film carrier glass fiber filter cloth |
| CN110007076A (en) * | 2019-05-13 | 2019-07-12 | 无锡博慧斯生物医药科技有限公司 | A kind of whole blood sample detection device and its detection method |
| CN111419786A (en) * | 2019-01-09 | 2020-07-17 | 周定兰 | Composition for inhibiting or dissolving calcium oxalate calculus and preparation method and application thereof |
| CN111500550A (en) * | 2020-04-02 | 2020-08-07 | 北京翼方生物科技有限责任公司 | Filter medium capable of degrading human blood uric acid and preparation method thereof |
-
2020
- 2020-09-09 CN CN202010943318.9A patent/CN112076535B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2199351C1 (en) * | 2001-09-04 | 2003-02-27 | Петрик Виктор Иванович | Method of plasma blood clearance from uric acid and creatinine |
| CN1674955A (en) * | 2002-08-13 | 2005-09-28 | 阿尔比奥技术公司 | Selective plasma exchange therapy |
| CN104168934A (en) * | 2012-01-19 | 2014-11-26 | 贝克斯特国际公司 | Method and composition for removing uremic toxins in dialysis processes |
| CN106540344A (en) * | 2016-12-23 | 2017-03-29 | 上海江夏血液技术有限公司 | For treating the plasma filtering device and method of acute cerebral infarction |
| CN109091955A (en) * | 2018-08-07 | 2018-12-28 | 苏州华龙化工有限公司 | A kind of preparation method of film carrier glass fiber filter cloth |
| CN111419786A (en) * | 2019-01-09 | 2020-07-17 | 周定兰 | Composition for inhibiting or dissolving calcium oxalate calculus and preparation method and application thereof |
| CN110007076A (en) * | 2019-05-13 | 2019-07-12 | 无锡博慧斯生物医药科技有限公司 | A kind of whole blood sample detection device and its detection method |
| CN111500550A (en) * | 2020-04-02 | 2020-08-07 | 北京翼方生物科技有限责任公司 | Filter medium capable of degrading human blood uric acid and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112076359A (en) * | 2020-09-14 | 2020-12-15 | 江苏恰瑞生物科技有限公司 | Plasma adsorption filtering device for treating kidney stone and filtering method thereof |
| CN112076359B (en) * | 2020-09-14 | 2022-10-28 | 江苏恰瑞生物科技有限公司 | Plasma adsorption filtering device for treating kidney stone and filtering method thereof |
| CN116421808A (en) * | 2023-03-09 | 2023-07-14 | 江苏恰瑞生物科技有限公司 | Plasma adsorption and filtration device for asthma treatment and filtration method thereof |
| CN116421808B (en) * | 2023-03-09 | 2023-09-22 | 江苏恰瑞生物科技有限公司 | Plasma adsorption and filtration device for asthma treatment and filtration method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112076535B (en) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112076535B (en) | Biological enzyme-linked filter medium and preparation method thereof | |
| AU2015231764B2 (en) | Cartridges useful in cleaning dialysis solutions | |
| Edmunds Jr et al. | Relationship between platelet count and cardiotomy suction return | |
| JP2004502456A5 (en) | ||
| CN106139289B (en) | Semi-permeable membrane is layered integrated biological reactor | |
| WO2009086203A2 (en) | Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment | |
| CN108310503A (en) | A kind of Almightiness type plasma purification system based on centrifugal separation plasma method | |
| US20070289928A1 (en) | Plasma Exchange Waste Liquid Purification And Circulation Dialysis Apparatus | |
| CN104117104A (en) | Integrated blood purification device with blood perfusion structure and blood dialysis structure | |
| CN115192807A (en) | Oxygenator and extracorporeal membrane lung oxygenating device | |
| CN112426801B (en) | Preparation method of filter medium material | |
| JP2022514192A (en) | Methods and compositions for removing uremic toxins | |
| Lanjuan et al. | Severe hepatitis treated with an artificial liver support system | |
| CN112076359B (en) | Plasma adsorption filtering device for treating kidney stone and filtering method thereof | |
| CN109794172A (en) | A kind of preparation method of the antibacterial hollow-fibre membrane for blood purification | |
| CN1879900A (en) | In vitro molecular adsorption and circulation system | |
| CN208552669U (en) | A kind of Almightiness type plasma purification system based on centrifugal separation plasma method | |
| CN206027207U (en) | Coronary heart disease treatment filter | |
| CN218356829U (en) | Extracorporeal circulation connecting pipe for hemodialysis | |
| CN109745868A (en) | It is a kind of for treating the preparation method of uremic antibacterial hollow-fibre membrane | |
| EP2077869A1 (en) | A system and method for the extra-corporeal purification of blood of pathogenic enzymes | |
| CN116492991B (en) | Method for preparing filling material of blood perfusion device capable of removing TNF-alpha in blood | |
| Vanholder et al. | Single needle haemodialysis | |
| CN214911399U (en) | Multifunctional hemofiltration pipeline | |
| CN203694203U (en) | Electrode separation type dialysis device for treating heavy metal poisoning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Lili Inventor after: Gu Lingwei Inventor after: Lu Xuefeng Inventor after: Zhang Dingyi Inventor before: Zhang Lili |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |